TABLE 2.
CIs for inhibition of wt and drug-resistant HIV-1 variants by AZT-NNRTI combinations
| Virus | Drug combination | Ratio | CI at the following effective concna:
|
||
|---|---|---|---|---|---|
| 50% | 75% | 90% | |||
| wt | UC781-AZT | 1:1 | 1.1 ± 0.3 | 0.8 ± 0.2 | 0.7 ± 0.2 |
| UC781 resistant | UC781-AZT | 1:1 | 1.0 ± 0.1 | 1.1 ± 0.1 | 1.2 ± 0.1 |
| AZT resistant (691A clini-al isolate) | UC781-AZT | 1:1 | 0.3 ± 0.1 | 0.25 ± 0.1 | 0.2 ± 0.05 |
| Nevirapine-AZT | 1:1 | 1.2 ± 0.3 | 1.2 ± 0.2 | 1.4 ± 0.3 | |
| 5:1 | 1.8 | 1.5 | 1.3 | ||
| 10:1 | 0.5 | 0.5 | 0.6 | ||
| TSAO-AZT | 1:1 | 1.5 | 1.2 | 1.0 | |
| 10:1 | 0.9 | 0.95 | 1.0 | ||
a
CIs were calculated by the method of Chou and Talalay (10). The values reported are the means ± standard deviation from at least three independent experiments conducted with duplicate samples. Values without standard deviations are the averages from two independent experiments conducted in duplicate.